(NOTE: There is an ongoing debate about whether 5-Amino 1MQ should be classified as a small molecule or a peptide, but thats a discussion far beyond the scope of this article) It was discovered in 2017 by researchers at the University of Texas who were attempting to discover small, selective, and membrane-permeable inhibitors of an enzyme called nicotinamide N -methyltransferase (NNMT)
AOD 9604 is usually provided via subcutaneous injections, often combined with other weight-loss management in participants who find it challenging to lose stubborn fat or have metabolism slowdowns
The pattern is consistent: accelerated healing timelines in animal models, minimal adverse effects, and a glaring absence of Phase I or Phase II human trials that would validate these findings in clinical populations
Possible side effects may include redness or irritation at the injection site, headache, flushing, or mild dizziness
Key Features: Potent NNMT inhibitor linked to improved cellular metabolism